All In Biotech

Drug Trial Radar · NCT05645536

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Open-label, Safety Extension Study for Subjects With HR+, HER2-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer OVELIA Study

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

250

Planned (sponsor's estimate)

Start

Dec 28, 2022

Primary completion

Mar 2030

Study completion Mar 2030

Sponsor

Lead sponsor
Tolmar Inc.Industry
Sponsor type
Industry
First posted
Dec 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 51 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer. The TOL2506A-EXT study described here is a safety extension study to assess and collect long-term data on the ongoing safety and tolerability of TOL2506 in combination with tamoxifen or an AI for up to 4 years.

Conditions

  • Breast Cancer

Interventions

  • TOL2506Drug

    Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months

  • TamoxifenDrug

    20 mg once daily or 10 mg 2 times daily - either tablet of solution

  • Letrozole tabletsDrug

    One 2.5 mg tablet taken orally once daily

  • Anastrozole TabletsDrug

    One 1 mg tablet taken orally once daily

  • Exemestane TabletsDrug

    One 25 mg tablet taken orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The occurrences of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: 4 years from enrolling in study

Locations

46 sites in 6 countries. Site status is shown where the registry gives one.

  • Marin Cancer Care, Inc.

    Greenbrae, California

  • Holy Cross Hospital

    Fort Lauderdale, Florida

  • Baptist Health Lexington

    Lexington, Kentucky

  • Baptist Health Louisville

    Louisville, Kentucky

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland

  • Hematology Oncology Associates of Central New York, PC

    East Syracuse, New York

  • Cape Fear Valley Health Systems - Cancer Center

    Fayetteville, North Carolina

  • Lankenau Medical Center

    Wynnewood, Pennsylvania

  • Tennessee Oncology, PLLC

    Chattanooga, Tennessee

  • Tennessee Oncology

    Nashville, Tennessee

  • Texas Oncology - Central South

    Austin, Texas

  • Texas Oncology - Presbyterian Cancer Center

    Dallas, Texas

  • Texas Oncology - Northeast Texas

    Longview, Texas

  • Joe Arrington Cancer Research and Treatment Center at Covenant Children's Hospital

    Lubbock, Texas

  • Texas Oncology - San Antonio

    New Braunfels, Texas

  • Texas Oncology - DFW

    Plano, Texas

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Hospital Aleman

    Caba, Argentina

  • Fundacion CENIT

    CABA, Argentina

  • Instituto Oncologico de Cordoba (IONC)

    Córdoba, Argentina

  • Centro Privado de MRI de Rio Cuarto SA

    Córdoba, Argentina

  • Sanatorio Allende

    Córdoba, Argentina

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Santa Fe Province, Argentina

  • Instituto de Educacao, Pesquisa e Gestao em Saude

    Rio de Janeiro, Brazil

  • Centro de Estudos e Pesquisa de Hematologia e Oncologia

    Santo André, Brazil

  • Fundacao Pio XII - Hospital de Amor Barretos

    São Paulo, Brazil

  • Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil

  • Hospital Araujo Jorge

    Goiânia, Goiás, Brazil

  • Hospital do Cancer de Londrina

    Londrina, Paraná, Brazil

  • Irmandade Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Uniao Brasileira de Educacao e Assistencia

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Amor Amazonia

    Porto Velho, Rondônia, Brazil

  • Unique Hospital Multispecialty & Research Institute

    Surat, Gujarat, India

  • SRV AGADI Hospital and Research Centre

    Bangalore, Karnataka, India

  • Oncoville Cancer Hospital and Research Centre

    Bengaluru, Karnataka, India

  • Mysore Medical College and Research Institute

    Mysore, Karnataka, India

  • KIMS - Kingsway Hospitals

    Nagpur, Maharashtra, India

  • Indrayani Hospital and Cancer Institute

    Pune, Maharashtra, India

  • Erode Cancer Centre Private Ltd.

    Erode, Tamil Nadu, India

  • Swami Harshankaranand Ji Hospital & Research Centre

    Varanasi, Uttar Pradesh, India

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.